Comment on: Identification of antimicrobial activity among FDA-approved drugs for combating mycobacterium abscessus and mycobacterium chelonae

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 252-253

  Mukherjee, Tathagata ^a   Boshoff, Helena ^a   Barry III, Clifton E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

M.abscessus; Metronidazole; PA 824

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; CLARITHROMYCIN; COPPER; HYDROGEN PEROXIDE; IRON; METRONIDAZOLE; TUBERCULOSTATIC AGENT;

ACTINOMYCETALES INFECTION; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE SEQUENCE; LETTER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; NONHUMAN; TUBERCULOSIS; DRUG SCREENING; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; NOTE;

ANTITUBERCULAR AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 84859193801     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr418     Document Type: Letter

References (13)

1. Chopra S, Matsuyama K, Hutson C et al. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob Chemother 2011;66: 1533-6.
2. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Resp Crit Care 2007; 175: 367-416.
3. Stover CK, Warrener P, VanDevanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-6.
4. Zelazny AM, Calhoun LB, Li L et al. Identification of Mycobacteriumspecies by secA1 sequences. J Clin Microbiol 2005; 43: 1051-8.
5. Saleeb PG, Drake SK, Murray PR et al. Identification of mycobacteria in solid-culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2011; 49: 1790-4.
6. Roe VA. Antimicrobial agents: pharmacology and clinical application in obstetric, gynecologic, and perinatal infections. J Obstet Gynecol Neonatal Nurs 1999; 28: 639-48.
7. Roe FJC. Metronidazole-review of uses and toxicity. J Antimicrob Chemother 1977; 3: 205-12.
8. Veldhuyzen van Zanten SJ, Sherman PM, Hunt RH. Helicobacter pylori: new developments and treatments. CMAJ 1997; 156: 1565-74.
9. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 2054-8.
10. Edwards DI. Nitroimidazole drugs-action and resistance mechanisms. 1. Mechanisms of action. J Antimicrob Chemotherapy 1993; 31: 9-20.
11. Perezreyes E, Kalyanaraman B, Mason RP. The reductive metabolism of metronidazole and ronidazole by aerobic liver microsomes. Mol Pharmacol 1980; 17: 239-44.
12. Thompson SA, Blaser MJ. Isolation of the Helicobacter pylori recA gene and involvement of the recA region in resistance to low pH. Infect Immun 1995; 63: 2185-93.
13. Yeung TC, Beaulieu BB, Mclafferty MA et al. Interaction of metronidazole with DNA repair mutants of Escherichia coli. Antimicrob Agents Chemother 1984; 25: 65-70.